IRIS

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results / Sharma, P; Siefker-Radtke, A; De Braud, F; Basso, U; Calvo, E; Bono, P; Morse, Ma; Ascierto, P; Lopez-Martin, J; Brossart, P; Rohrberg, K; Mellado, B; Fischer, Bs; Meadows-Shropshire, S; Saci, A; Callahan, Mk; Rosenberg, J. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 37:19(2019). [10.1200/JCO.19.00538]

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Ascierto P;
2019
2019
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results / Sharma, P; Siefker-Radtke, A; De Braud, F; Basso, U; Calvo, E; Bono, P; Morse, Ma; Ascierto, P; Lopez-Martin, J; Brossart, P; Rohrberg, K; Mellado, B; Fischer, Bs; Meadows-Shropshire, S; Saci, A; Callahan, Mk; Rosenberg, J. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 37:19(2019). [10.1200/JCO.19.00538]
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014302
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 214
  • ???jsp.display-item.citation.isi??? 196
social impact